Le Lézard
Classified in: Health, Science and technology
Subject: OFR

Stealth BioTherapeutics Announces Closing of $3.2 Million Registered Direct Offering


BOSTON, Nov. 24, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the closing of its previously announced registered direct offering of 2,844,446 of its American Depositary Shares ("ADSs"), each ADS representing 12 ordinary shares of the Company.  The purchase price for one ADS was $1.125.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The gross proceeds from this offering were approximately $3.2 million.

The ADSs described above were offered pursuant to a "shelf" registration statement (File No. 333-237542) filed with the Securities and Exchange Commission (SEC) and declared effective on April 10, 2020. The ADSs were offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A prospectus supplement and the accompanying prospectus relating to the offering of the ADSs were filed with the SEC on November 20, 2020. Electronic copies of the prospectus supplement and the accompanying prospectus relating to the offering of ADSs may be obtained on the SEC's website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by e-mail: placements@hcwco.com or by telephone: (646) 975-6996.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About Stealth

We are a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function.

Investor Relations 

Stern Investor Relations
Janhavi Mohite, 212-362-1200
IR@StealthBT.com

SOURCE Stealth BioTherapeutics Inc.


These press releases may also interest you

at 21:50
Bentley Systems, Incorporated ("Bentley"), the infrastructure engineering software company, announced today the pricing of $600.0 million aggregate principal amount of convertible senior notes due 2026 (the "Notes") in a private offering to...

at 21:35
Guotai Junan International Holdings Limited ("Guotai Junan International", the "Group" or the "GTJAI", Stock code:1788.HK) announced that the Group will join hands with Nan Fung Group and Prospect Avenue Capital (PAC) to collaboratively boost...

at 21:15
iLOOKABOUT Corp. ("ILA" or "the Company") today announced that it has retained Paradox Public Relations Inc. ("Paradox") to provide investor relations services, effective immediately. Paradox is based in Montreal, QC. Paradox has been engaged to...

at 21:00
JAPONISME is a tour brand that will refine the impressions of Japan that one may already have by creating memorable experiences based on authenticity. Participants can join online tours from anywhere in the world, as the main service of the company...

at 21:00
Mirror, the synthetic assets protocol built on the Terra blockchain, has completed the integration of a cross-chain bridge to Binance Smart Chain (BSC) -- bringing synthetic assets to the BSC community. The bridge enables porting of Terra's...

at 20:37
Invitae Corporation today announced the pricing of an underwritten public offering of 7,766,990 shares of its common stock at a price to the public of $51.50 per share. All of the shares are being sold by Invitae. The gross proceeds to Invitae from...



News published on 24 november 2020 at 16:30 and distributed by: